Radiotheranostic Agents in Hematological Malignancies

Frontiers in Immunology

Elodie Duray¹  Mireille Dumoulin¹  Kim De Veirman²  Louise Vrancken³  Jo Caers³  Nadia Withofs⁴  Amelie Eriksson Karlström⁵  Valentina Bocuzzi⁶  Guillaume Marcion⁶  Margaux Lejeune⁶  Matthias D’Huyvetter⁷  Nick Devoogdt⁷  Ahmet Krasniqi⁷ 

[1] Centre for Protein Engineering, Inbios, University of Liège, Liège, Belgium;Department of Hematology and Immunology, Vrije Universiteit Brussel, Brussels, Belgium;Department of Hematology, CHU de Liège, Liège, Belgium;Department of Nuclear Medicine, CHU de Liège, Liège, Belgium;Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden;Laboratory of Hematology, GIGA I³, University of Liège, Liège, Belgium;Laboratory of In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium;

关键词: lymphoma;    leukemia;    multiple myeloma;    radiotheranostic;    radionuclide;   

DOI  :  10.3389/fimmu.2022.911080

来源: DOAJ

【 摘 要 】

Radioimmunotherapy (RIT) is a cancer treatment that combines radiation therapy with tumor-directed monoclonal antibodies (Abs). Although RIT had been introduced for the treatment of CD20 positive non-Hodgkin lymphoma decades ago, it never found a broad clinical application. In recent years, researchers have developed theranostic agents based on Ab fragments or small Ab mimetics such as peptides, affibodies or single-chain Abs with improved tumor-targeting capacities. Theranostics combine diagnostic and therapeutic capabilities into a single pharmaceutical agent; this dual application can be easily achieved after conjugation to radionuclides. The past decade has seen a trend to increased specificity, fastened pharmacokinetics, and personalized medicine. In this review, we discuss the different strategies introduced for the noninvasive detection and treatment of hematological malignancies by radiopharmaceuticals. We also discuss the future applications of these radiotheranostic agents.

【 授权许可】

Unknown